In The Lancet Diabetes & Endocrinology, Henry Bone and colleagues reported results of denosumab administration for up to 7 or 10 years in postmenopausal women with osteoporosis.¹ Participants who had completed the randomised FREEDOM trial were offered to participate in the open-label, 7-year extension, receiving 60 mg of denosumab subcutaneously every 6 months.

中文翻译：

---

地诺单抗治疗绝经后骨质疏松症妇女

在《柳叶刀糖尿病与内分泌学》杂志上，亨利·伯恩（Henry Bone）及其同事报道了绝经后骨质疏松症妇女中地诺单抗给药长达7或10年的结果。¹名完成了免费FREEDOM随机试验的与会人员将参加开放标签的7年扩展期，每6个月皮下注射denosumab 60 mg。